Starting at $ 115 / Month GLP-1 receptor agonist that is FDA-approved for chronic weight management Wegovy Adults with obesity (BMI 30) or overweight (BMI 27 with a weight-related condition such as hypertension, diabetes, or high cholesterol) Start todayMore Info Potential Weight Loss* Administration methods** Injections Dose frequency*** Weekly Potential side effects Possible side effects may include nausea, vomiting, constipation, diarrhea, indigestion or stomach discomfort, reduced appetite, headache, fatigue, or injection site reactionsespecially when starting or increasing the dose
et al., The Journal of Clinical Endocrinology & Metabolism 2
The obesity rate of the US, after years of uncontrolled growth, started to rise above, but at a level that allowed consistency, leading the developed world
Pregnant individuals should consult their provider
A GLP-1/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome
treatment in pregnancy treatment in pregnancy Multidisiplinary discussion is recommended, involving toxicology/poison control (1-800-222-1222) and hematology